Amazingly, the CDC owns “the” patent on Ebola and all future strains.
The “SUMMARY OF THE INVENTION” section of the patent document also clearly claims that the U.S. government is claiming “ownership” over all Ebola viruses that share as little as 70% similarity with the Ebola it “invented”:
Why would a government organization claim to have “invented” this infectious disease and then claim a monopoly over its exploitation for commercial use? It is clear that the CDC plans to claim royalties on Ebola vaccines. This certainly increases the likelihood that the vaccines will become mandatory, thus increasing the profit potential for the patent holders…
Gates has announced that he plans to vaccinate every child in the third world with multiple vaccines, which could result in a dramatic population reduction of 10-15%. Do you realize the enormous profits that can be realized by vaccinating every child in the third world? If we apply Gates’ penchant for investing in causes which produce a hefty “return on investment” (ROI) then one could reasonably suspect that Gates is positioning himself to profit on the $50 million he has invested in the Ebola cause which conveniently includes the CDC, the holder of the patent for Ebola.
The NIH presently holds all patents on Ebola vaccines. Crucell is much like Tekimara is to Monsanto in that they are fronting the science for the Ebola vaccine treatment patents.
What You Are Not Being Told: Fast facts From Crucell’s Website
Crucell is developing an Ebola vaccine in collaboration with the Vaccine Research Center (VRC) of the NIH National Institute of Allergy and Infectious Diseases (NIAID). It has been shown to completely protect monkeys against the virus with a single dose of the vaccine.
Under the terms of the agreement with VRC, Crucell has an option for exclusive worldwide commercialization rights to the Ebola vaccine.
Crucell’s Ebola vaccine entered Phase I clinical trials in Q3 2006. Two groups of 16 volunteers were enrolled and vaccinated. The study showed safety and immunogenicity at the doses evaluated.
In October 2008, Crucell secured a NIAID/NIH award to advance the development of Ebola and Marburg vaccines, with the ultimate aim of developing a multivalent filovirus vaccine.
The award provides funding of up to $30 million, with additional options, worth a further $40 million…